Biosensors Enters Into Licensing Agreement with Eurocor For Drug-Eluting Balloon Range

May 31, 2013—Biosensors International Group, Ltd. (Singapore) has entered into a licensing agreement with Eurocor GmbH, a group company of Opto Circuits (India) Ltd. (Karnakata, India), for their drug-eluting balloon (DEB) technology and related intellectual property rights in relation to the treatment of both coronary and peripheral artery disease. As a first step in this process, an original equipment manufacturer arrangement is being implemented, whereby Biosensors will market and sell, under its own brand, DEBs manufactured by Eurocor. Both agreements will involve three Biosensors-branded DEBs: BioStream, BioPath 014, and BioPath 035.

All three devices are DEB dilatation catheters designed for percutaneous transluminal angioplasty. BioStream has been developed for use in coronary arteries, and the two BioPath DEBs have been optimized for the treatment of patients with peripheral arterial disease. BioPath 035 is intended for peripheral intervention above the knee and BioPath 014 for infrapopliteal intervention below the knee. All three DEBs feature Eurocor's paclitaxel coating technology, which has been proven in several clinical studies performed by Eurocor, including the global Valentine I and II registries, the company stated.

The company anticipates CE Mark approval within the next 6 weeks. After that, BioStream, BioPath 014 and BioPath 035 will be launched in major European markets and selected regions in the Middle East, Africa, and Asia, the company advised.